Post-transplantation lymphoproliferative disease in heart and heart–lung transplant recipients: 30-year experience at Stanford University

Gao, Shao Zhou; Chaparro, Sandra; Perlroth, Mark G.; Montoya, José G.; Miller, Joan; Dimiceli, Sue; Hastie, Trevor; Oyer, P E; Schroeder, John S.

doi:10.1016/s1053-2498(02)01229-9

Cited by 140 publications

(109 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Analysis of the critical 12-months data showed that use of anti IL-2 receptor antibodies was not associated with an increased risk of lymphoma (Gao et al, 2004) (Figure 1). There is no conclusive evidence that development of PTLD is associated with a single immunosuppressive agent (Gao et al, 2003;Pirsch et al, 1997;Weisner et al, 1998;Younes et al, 2000). Also the effect of everolimus and sirolimus on PTLD development is not clear.…”

Section: Risk Factorsmentioning

confidence: 99%

Post-Trasplant Lymphoproliferative Disorders (PTLD) in Adult Kidney Trasplantated Patients

Aversa¹,

Stragliotto²,

Canova³

et al. 2011

After the Kidney Transplant - The Patients and Their Allograft

View full text Add to dashboard Cite

Section: Risk Factorsmentioning

confidence: 99%

Post-Trasplant Lymphoproliferative Disorders (PTLD) in Adult Kidney Trasplantated Patients

Aversa¹,

Stragliotto²,

Canova³

et al. 2011

After the Kidney Transplant - The Patients and Their Allograft

View full text Add to dashboard Cite

“…In 1984 -1998, when the use of cyclosporine became more prevalent, 34 patients were diagnosed with PTLD, indicating a link between the drug and the development of malignancy. Multiple studies have demonstrated an association between the onset of lymphoma and the use of OKT3, tacrolimus, and high-dose cyclosporine [6,31,35,36].…”

Section: Pathophysiologymentioning

confidence: 99%

Malignancy After Solid Organ Transplantation: An Overview

2008

View full text Add to dashboard Cite

Disclosure:This article discusses the use of acitretin (manufactured by Connetics) for prophylaxis of non-melanoma skin cancers; cyclophosphamide * (Bristol-Myers Squibb), adriamycin * (Pharmacia), prednisone * (Pfizer), vindesine (Lilly/EG Labo; not available in the U.S.), rituximab * (Genentech), and monoclonal anti-IL-6-antibody (multiple manufacturers) for post-transplant lymphoproliferative disorder (PTLD) (clinical trial); vincristine * (Lilly/Gensia Sicor) and bleomycin * (Bristol-Myers Squibb) for PTLD and Kaposi's sarcoma (KS); liposomal daunorubicin (Gilead) for KS (indicated for HIV-associated KS); paclitaxel (BristolMyers Squibb) for KS (indicated for AIDS-associated KS); imatinib (Novartis) and bevacizumab (Genentech) for KS; and matrix metalloproteinase inhibitor COL-3 (CollaGenex) for KS (clinical trial). ( * Drugs marked with asterisks are indicated for use in malignant lymphomas generally, but no specific mention is made of PTLD.)The content of this article has been reviewed by independent peer reviewers to ensure that it is balanced, objective, and free from commercial bias. No financial relationships relevant to the content of this article have been disclosed by the authors, planners, independent peer reviewers, or staff managers. LEARNING OBJECTIVESAfter completing this course, the reader should be able to:1. Describe the most common malignancies encountered after solid organ transplantation.2. Discuss the pathogenesis of malignancy after solid organ transplantation. Administer standard treatment for common post-solid organ transplantation malignancies.This article is available for continuing medical education credit at CME.TheOncologist.com. CME CME ABSTRACT CASE PRESENTATIONA 49-year-old man with no prior medical history initially presented with severe dyspnea progressive over 6 months.The patient underwent an open-lung biopsy that confirmed the diagnosis of idiopathic pulmonary fibrosis. He was assessed for lung transplantation. An extensive pretransplant

show abstract

“…There is no conclusive evidence that development of PTLD is associated with a single immunosuppressive agent (Gao SZ et al, 2003;Pirsch JD et al, 1997;Weisner RH et al, 1998;Younes BS et al, 2000). Also the effect of everolimus and sirolimus on PTLD development is not clear.…”

Section: Introductionmentioning

confidence: 99%